[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Crisà et al., 2020 - Google Patents

Atypical chronic myeloid leukemia: where are we now?

Crisà et al., 2020

View HTML
Document ID
8060949204899091744
Author
Crisà E
Nicolosi M
Ferri V
Favini C
Gaidano G
Patriarca A
Publication year
Publication venue
International Journal of Molecular Sciences

External Links

Snippet

Atypical chronic myeloid leukemia, BCR-ABL1 negative (aCML) is a rare myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) with a high rate of transformation to acute myeloid leukemia, and poor survival. Until now, the diagnosis has been based on …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/01—Social networking

Similar Documents

Publication Publication Date Title
Crisà et al. Atypical chronic myeloid leukemia: where are we now?
Saultz et al. Acute myeloid leukemia: a concise review
Shiraz et al. The current genomic and molecular landscape of Philadelphia-like acute lymphoblastic leukemia
Piccini et al. Venetoclax-based regimens for relapsed/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience
Katagiri et al. Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia
Ivanov et al. Pediatric acute lymphoblastic leukemia emerging therapies—From pathway to target
Tang et al. Identification of CD73 as a novel biomarker encompassing the tumor microenvironment, prognosis, and therapeutic responses in various cancers
Seipel et al. BMI1-Inhibitor PTC596 in combination with MCL1 inhibitor S63845 or MEK inhibitor trametinib in the treatment of acute leukemia
Guo et al. Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast cancer patient-derived xenograft models
Rebuzzi et al. Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: A review of the current evidence
Geissler et al. Correlation of RAS-pathway mutations and spontaneous myeloid colony growth with progression and transformation in chronic myelomonocytic leukemia—a retrospective analysis in 337 patients
Liu et al. Differential targeting of Gr-MDSCs, T cells and prostate cancer cells by dactolisib and dasatinib
Gerke et al. Definitions, Biology, and current therapeutic landscape of myelodysplastic/myeloproliferative neoplasms
Barwe et al. Imetelstat induces leukemia stem cell death in pediatric acute myeloid leukemia patient-derived xenografts
Awada et al. A focus on intermediate-risk acute myeloid leukemia: sub-classification updates and therapeutic challenges
Tseng et al. A review of Childhood Acute myeloid leukemia: diagnosis and Novel Treatment
Hennawi et al. Genomic landscape of mixed-phenotype acute leukemia
Kotogány et al. Imidazo [1, 2-b] pyrazole-7-carboxamide derivative induces differentiation-coupled apoptosis of immature myeloid cells such as acute myeloid leukemia and myeloid-derived suppressor cells
Lopes-Brás et al. Genomic profiling of sarcomas: a promising weapon in the therapeutic arsenal
Passariello et al. PATZ1 is overexpressed in pediatric glial tumors and correlates with worse event-free survival in high-grade gliomas
Tompa et al. Epigenetic suppression of the IL-7 pathway in progressive glioblastoma
Boden et al. A systematic review of mesenchymal epithelial transition factor (MET) and its impact in the development and treatment of non-small-cell lung cancer
Chatzikalil et al. Venetoclax combination treatment of acute myeloid leukemia in adolescents and young adult patients
Al-Amleh et al. Investigation of the effect of imatinib and hydroxyurea combination therapy on hematological parameters and gene expression in chronic myeloid leukemia (CML) patients
Nicolosi et al. Precision medicine in systemic mastocytosis